TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Background: TNFα blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS). Objective: To identify parameters predicting the clinical response to TNF ...

Attempts to design small molecule therapies directed to this cytokine have not led to approved products yet. Here we report the discovery and development of a potent small molecule inhibitor of TNF ...

TNF blockers, which work by attaching to and impeding chemical messengers behind inflammation, have had a significant impact on the treatment of RA. They have also been linked to lymphoma among users.

TNF inhibitor users had a lower risk for hip and spine fractures (adjusted odds ratio [aOR], 0.75; 95% CI, 0.62-0.91) than NSAID users, but this protective association was not seen in csDMARD users.

TNF Pharmaceuticals (TNFA) announced that it has achieved a safety data milestone supporting expanded and longer-term clinical studies of its ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Worries that ...

In fact, rates of adverse events such as respiratory hospitalization, death from lung disease, and all-cause mortality were numerically higher in the non-TNF inhibitor users -- hazard ratios ...